TY - JOUR
T1 - Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy
T2 - Temporal pattern and clinical predictors
AU - Gasparini, Maurizio
AU - Regoli, François
AU - Ceriotti, Carlo
AU - Galimberti, Paola
AU - Bragato, Renato
AU - De Vita, Stefano
AU - Pini, Daniela
AU - Andreuzzi, Bruno
AU - Mangiavacchi, Maurizio
AU - Klersy, Catherine
PY - 2008/3
Y1 - 2008/3
N2 - Background: The aim of the study was to determine whether cardiac resynchronization therapy (CRT) may induce a heart failure (HF) remission phase (recovery to New York Heart Association functional class I-II and regression of left ventricular [LV] dysfunction: LV ejection fraction [EF] ≥50%) and to define the incidence and predictors of such a process. Methods: Cardiac resynchronization therapy devices were successfully implanted in 520 consecutive HF patients from 1999 to 2006 (mean age 66 years, 82% male sex, New York Heart Association class ≥II, LVEF 28%, QRS 164 milliseconds, 6-minute hall walk distance 302 m) at our institution. Follow-up data were prospectively collected every 3 to 6 months. Continuous variables were stratified in tertiles. Results: Over a median follow-up of 28 months, 26% of patients achieved LV remission (rate: 16 per 100 person-years). At univariate analysis, female sex (P = .032), non-coronary artery disease (CAD) etiology (P <.001), mitral regurgitation
AB - Background: The aim of the study was to determine whether cardiac resynchronization therapy (CRT) may induce a heart failure (HF) remission phase (recovery to New York Heart Association functional class I-II and regression of left ventricular [LV] dysfunction: LV ejection fraction [EF] ≥50%) and to define the incidence and predictors of such a process. Methods: Cardiac resynchronization therapy devices were successfully implanted in 520 consecutive HF patients from 1999 to 2006 (mean age 66 years, 82% male sex, New York Heart Association class ≥II, LVEF 28%, QRS 164 milliseconds, 6-minute hall walk distance 302 m) at our institution. Follow-up data were prospectively collected every 3 to 6 months. Continuous variables were stratified in tertiles. Results: Over a median follow-up of 28 months, 26% of patients achieved LV remission (rate: 16 per 100 person-years). At univariate analysis, female sex (P = .032), non-coronary artery disease (CAD) etiology (P <.001), mitral regurgitation
UR - http://www.scopus.com/inward/record.url?scp=39149122892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39149122892&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2007.10.028
DO - 10.1016/j.ahj.2007.10.028
M3 - Article
C2 - 18294488
AN - SCOPUS:39149122892
VL - 155
SP - 507
EP - 514
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 3
ER -